Lenalidomide for keeping IgG4-related disease in remission
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests whether a medication called lenalidomide helps keep your IgG4-related disease in remission and prevents it from coming back. It is for people whose disease is well controlled on low-dose steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with IgG4-related disease and are currently in remission (no active symptoms) after steroid treatment.
- Your disease has been stable without flares for at least 12 months.
- You have been taking a low dose of prednisone (or equivalent) — 7.5 mg per day or less — for at least 6 months.
- You have not used lenalidomide before and are not allergic to it.
- You do not have serious infections, blood disorders, liver or kidney problems, or a history of blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
This study looks at a specific immune signal (C5a) in people with IgG4-related disease to see if it could be a target for future treatments. It compares patients with active disease, those in remission, and healthy volunteers to understand how this signal changes.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This trial is studying treatment plans for people with IgG4-related disease that affects a surface (superficial) organ area. It focuses on people who are newly diagnosed or have come back and who need to start or continue steroid medicine at a low dose.
This study tests a new drug (IMM0306) combined with lenalidomide, compared to a placebo with lenalidomide, for people with follicular lymphoma that has come back or not responded to treatment. The goal is to see if adding IMM0306 helps control the cancer better.
Hear when a new Immunoglobulin G4-Related Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.